CONTOURA vs WFO Ablation PRK & LASIK

Sponsor
59th Medical Wing (U.S. Fed)
Overall Status
Recruiting
CT.gov ID
NCT05037370
Collaborator
(none)
400
1
2
30.3
13.2

Study Details

Study Description

Brief Summary

This is a prospective randomized contralateral double-masked study. Each patient will be randomized as to which eye undergoes wave-front optimized (WFO) vs. wave-front guided (WFG) during Photorefractive keratectomy (PRK) or Laser-assisted in situ Keratomileusis (LASIK) surgery to determine which ablation profile provides the best visual outcome.

Condition or Disease Intervention/Treatment Phase
  • Device: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation
N/A

Detailed Description

In 2015, the FDA approved a new laser ablation profile for performing laser corneal refractive surgery. Multiple sophisticated profiles have been developed in an attempt to optimize visual outcomes and reduce post-operative lower and higher-order optical aberrations. Among these include wave-front optimized (WFO) and wave-front guided (WFG) ablation profiles. The former compensated for corneal curvature to reduce spherical aberration and the latter, a more complicated ablation profile, was designed to minimize specific aberrations in an individual eye. Topographic profiles have also been used for over 17 years. These profiles consider the shape of the anterior corneal surface. The newest such topographic ablation profile, Contoura Vision, is a topography guided (TG) profile that, based on over 22,000 curvature data points captured using the VARIO Topolyzer, individualizes the ablation pattern. For comparison, WFO uses a patient's estimated average corneal curvature alone to create an ablation pattern. The addition of the VARIO Topolyzer adds a significant increase of pre-operative patient preparation. Anecdotally, between 1-3hrs of additional technician hours are required to prepare a patient for the Contoura Vision TG ablation profile.

This will be a prospective randomized contralateral double-masked study. Patients will undergo the same standard of care preoperative evaluation and education as any other patient not enrolled in the study. The physician performing surgery will choose either LASIK or PRK, taking into account patient preference, preoperative data and overall clinical picture, ultimately choosing which is best for the patient. If a patient qualifies for both, the patient may choose either LASIK or PRK. Each patient will be randomized as to which eye undergoes a WFO treatment vs Contoura. At the time of surgery the patient will be blinded as to which eye receives which treatment, but the surgical team will not be blinded as to which procedure is performed. Post-operatively, the ophthalmic technicians and optometrists responsible for postoperative examinations (measurement of visual acuity, refractions, transcription of PRO's) will be blinded as to which eye underwent Contoura vs WFO. While treatments will vary, both have the same safety profile. Both involve sophisticated lasers to change the shape of the cornea to achieve the desired outcome. The variance comes in the type of pattern the laser uses to treat each individual. All post-operative care will be standard of care with medications being the same as if the patient were not enrolled in the study. Post-operative evaluations will take place at postoperative day 1, week 1, month 1, month 3, and month 6.

All data collected will be standard pre- and post-operative ophthalmic refractive surgery measurements. This includes a standard medical history, especially to include prior eye surgeries or diseases. Pre-operative measurements include vision assessments, contrast sensitivity, pre- and post-dilation as well as keratometry and axial length measurements. The Contoura requires a separate set of data collection via the VARIO topolyzer. Intraoperative data collected will include variables such as actual treatment outcomes and laser settings. Post-operative measurements will consist of many of the same measurements as those obtained preoperatively including uncorrected and corrected visual acuity, and refractive measurements. A symptoms-based questionnaire specific to corrective eye surgery (PROWL) will be given to patients before and after surgery during routine follow-ups. Each PROWL is specific to an individual eye, not specific to the surgery performed in each eye (i.e. the same PROWL questionnaire will be used regardless of whether the patient underwent PRK or LASIK). All PROWL data will be compared pre- and post-operatively and will be stratified based on surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized contralateral double-masked studyRandomized contralateral double-masked study
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
Patient will be blinded as to which eye receives which treatment, but the surgical team will not be blinded as to which procedure is performed. Post-operatively, the ophthalmic technicians and optometrists responsible for postoperative examinations will be blinded as to which eye underwent Contoura vs WFO.
Primary Purpose:
Treatment
Official Title:
Topography-guided vs. Wavefront Optimized Corneal Refractive Surgery: A Prospective Contralateral Randomized Double-masked Study
Actual Study Start Date :
Apr 22, 2021
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
Oct 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: LASIK refractive surgery

Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

Device: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation
Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye

Experimental: PRK refractive surgery

Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

Device: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation
Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye

Outcome Measures

Primary Outcome Measures

  1. Post-operative refractive error [6 months post-surgery]

    The Post-Operative sphere equivalent refractive error for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

Secondary Outcome Measures

  1. Post-operative Uncorrected Visual Acuity [6 months post-surgery]

    The Post-Operative visual acuity for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Meet requirements for PRK or LASIK i.e., Stable <= .5 D change MRSE)

  • DOD beneficiaries age 21-50 years

  • Local pts (w/i 60 mi) who will be in the area for at least 6 months post surgery

  • Willing to complete all required follow-up visits

Exclusion Criteria:
  • No meeting requirements for PRK or LASIK

  • Desiring monovision treatment

  • Anisometropia >2D spherical equivalent

  • Prior ocular surgeries / trauma / problem

  • History of dry eyes

  • Hyperopia

  • Mixed astigmatism

  • Inability to capture VARIO topolyzer scans

  • Pregnant (or who plans to be within 6 months after surgery)

  • Breastfeeding any time during the study

  • History of herpetic disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Joint Warfighter Refractive Surgery Center at WHASC San Antonio Texas United States 78236

Sponsors and Collaborators

  • 59th Medical Wing

Investigators

  • Principal Investigator: CHARISMA B EVANGELISTA, MD, 59th Medical Wing

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
59th Medical Wing
ClinicalTrials.gov Identifier:
NCT05037370
Other Study ID Numbers:
  • FWH20200077H
First Posted:
Sep 8, 2021
Last Update Posted:
Sep 8, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by 59th Medical Wing

Study Results

No Results Posted as of Sep 8, 2021